Albumin News and Research

RSS

Type 2 diabetics with normoalbuminuria more likely to develop heart problems

In individuals with type 2 diabetes, any degree of measurable urinary protein excretion—even in what is considered the normal range—increases their risk of experiencing heart problems, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

31 Aug 2012

Healthcare announces important changes to the U.S. product label for Optison

GE Healthcare today announced important changes to the U.S. product label for Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy.

22 Aug 2012

Three alternative diabetes markers found

Experts have identified three alternative biomarkers that may be useful for picking up on diabetes risk.

13 Aug 2012

Lipid treatment absolved of hemorrhagic transformation guilt

The lipid profiles of patients undergoing thrombolysis for acute stroke predict their mortality risk but not their risk for symptomatic intracerebral hemorrhage, shows a large study.

1 Aug 2012

Diabetes cutoffs don’t quite cut it for South Asians

Individuals of South Asian origin may require closer monitoring for Type 2 diabetes, suggest researchers.

27 Jul 2012

Low serum albumin increases graft failure risk in kidney-transplant children

Children with hypoalbuminemia undergoing kidney transplantation are at an increased risk for graft failure, US research shows.

24 Jul 2012

Low serum albumin associated with higher risk of graft failure in pediatric kidney transplants

For children receiving kidney transplants, a potentially correctable blood condition present in about one in four recipients is associated with a moderately increased risk of the graft's later failure, suggesting that clinicians should weigh whether transplant is advisable when the condition is present, according to UC Davis research presented today at the 24th International Congress of the Transplantation Society in Berlin.

20 Jul 2012

Sanquin, Baxter enter manufacturing services agreement for plasma therapies

Baxter International Inc. today announced that it has entered into a manufacturing services agreement with Stichting Sanquin Bloedvoorziening (Sanquin Blood Supply Foundation) in the Netherlands that will provide Baxter up to 1.6 million liters of incremental plasma fractionation capacity annually to support global growth of plasma-derived treatments.

From Baxter International Inc. 20 Jul 2012

Single-step method can rapidly detect pathogens and chemical contaminants

Using nanoscale materials, researchers at the University of Georgia have developed a single-step method to rapidly and accurately detect viruses, bacteria and chemical contaminants.

20 Jul 2012

TGen's customized procedure produces high amounts of exosomes for treatment of CKD

Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.

12 Jul 2012

Vitrolife's EmbryoGlue medium increases implantation and pregnancy rates

In a study presented at the on-going ESHRE conference in Istanbul, Vitrolife's patent protected medium EmbryoGlue has once again been proven to increase both implantation and pregnancy rates, regardless of hormone stimulation of the endometrium or not.

4 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

3D printed templates of filament networks can improve function of engineered living tissues

Researchers are hopeful that new advances in tissue engineering and regenerative medicine could one day make a replacement liver from a patient's own cells, or animal muscle tissue that could be cut into steaks without ever being inside a cow.

2 Jul 2012

China SFDA approves China Biologic's Human Coagulation Factor VIII

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").

25 Jun 2012

Standard aspirin dose may not protect diabetics against blood clots

Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Too much salt can damage blood vessels and lead to hypertension

A high sodium intake over a prolonged period of time is associated with increased vascular dysfunction, which may lead to hypertension, researchers report.

22 Jun 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012

Serum PFOA levels increase cardiovascular risk factors

Serum levels of perfluorooctanoic acid, which is found in Teflon and Gore-Tex, appear to be associated with cardiovascular disease risk, even at levels commonly found in the general population, Korean investigators have discovered.

13 Jun 2012

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

8 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012